실적분석 2026년 8월 5일

Cencora ($COR) Q3 FY2026 Earnings Analysis — Adjusted EPS and Revenue Both Beat, Full-Year Guidance Raised

Earnings Scorecard

Revenue: $84.8 billion (+5.1% year-over-year; estimate $84.149 billion) ✅ Beat

EPS: Adjusted diluted $4.48 (estimate $4.35) ✅ Beat · GAAP diluted $3.94

Guidance: Raised — FY2026 adjusted diluted EPS $17.75–$17.95 (prior $17.70–$17.90)

Stock reaction: +3.19% after-hours ($316.05) — as of 08-05 20:51 KST

Positives

Adjusted EPS surprise: Q3 FY2026 adjusted diluted EPS of $4.48 beat the $4.35 estimate (+12.0% year-over-year)

Revenue and margins improving together: Revenue of $84.8 billion (+5.1%) paired with adjusted operating income of roughly $1.2 billion (+17.0%), with margin expansion

Full-year guidance raised and buyback executed: Adjusted diluted EPS outlook lifted to $17.75–$17.95; $1 billion in share repurchases completed during the quarter

Cencora is a U.S. prescription drug distribution and healthcare solutions provider. The key takeaway this quarter is less about the numbers themselves than the fact that earnings growth is running ahead of revenue growth. GAAP gross profit came in at $3.6 billion, up 24.1% year-over-year, with the gross margin expanding 66 basis points to 4.26%. The OneOncology acquisition, completed in February 2026, played a major role in lifting margins within the U.S. Healthcare Solutions segment.

Net income attributable to common shareholders reached $763.5 million in Q3 FY2026, up 11.1% year-over-year, while GAAP diluted EPS was $3.94 (+11.9%). U.S. Healthcare Solutions generated revenue of $74.9 billion (+4.9%) and operating income of $966.2 million (+15.9%), while International Healthcare Solutions also posted balanced growth, with revenue of $7.7 billion (+5.9%) and operating income of $165.9 million (+20.8%). The company repurchased $1 billion of stock during the quarter, completing the full-year plan ahead of schedule, and the diluted weighted-average share count fell 0.7% to 193.9 million shares.

Negatives

Sharp rise in net interest expense: Net interest expense of $140.7 million, up 72.0% year-over-year (related to acquisition financing)

Lower-margin product mix: Rising GLP-1 (diabetes/obesity treatments) sales partially offset gross margin expansion

Some pressure in U.S. distribution: Price declines on select brands, oncology customer attrition, and lower sales to a large mail-order customer

Earnings rose, but the financial cost burden climbed as well. To fund the OneOncology acquisition, Cencora tapped senior unsecured notes and a variable-rate term loan, which pushed net interest expense up by $58.9 million year-over-year. As a result, the growth in net income attributable to common shareholders (+11.1%) looks more modest than the GAAP operating income growth rate (+29.1%). Adjusted operating expenses also jumped 26.8% on acquisition-related costs, meaning the "price" of margin improvement is showing up in both operating costs and interest expense.

There are also points worth watching on the revenue side. Higher GLP-1-class sales boost the top line but carry lower margins, trimming the gross profit uplift. In U.S. distribution, price reductions from select branded drug manufacturers, the loss of an oncology customer in 2025, and lower sales to a large mail-order customer partially offset growth. The full-year guide assumes roughly $490 million in net interest expense and around $900 million in capital expenditure, both higher year-over-year, so free cash flow (projected at approximately $3.0 billion) needs to be monitored as well.

What Management Said

Management characterized the quarter as one in which the company's pharmaceutical-led strategy and organizational execution were validated by the numbers, and expressed confidence in both results and outlook as the basis for raising FY2026 adjusted EPS guidance. The tone stressed that investment in specialty pharmaceuticals, digital transformation, and people is strengthening customer support capabilities and the medium- to long-term growth platform, with the message that core business growth runway remains intact even as the fiscal year-end approaches.

For the guidance raise, the company cited both its full-year expectations and the buybacks completed in Q3. From the market's perspective, the more important read is that even though revenue didn't significantly outpace expectations, the company lifted adjusted earnings and full-year guidance. However, with acquisition effects and interest expense both expanding, "margin durability" and "absorption of financial costs" will need to be validated together in coming quarters.

Market Reaction and What to Watch Next

The market appears to have taken the combination of an adjusted EPS beat, a modest full-year guidance raise, and the already-executed large-scale buyback as a positive package. Revenue came in only marginally ahead of estimates, but margin improvement post-OneOncology and operating income growth across segments strengthened the narrative around "profitability over distribution scale." Higher interest expense and the lower-margin product mix remain risks, but the immediate post-release flow leans toward an interpretation that puts weight on earnings visibility and shareholder returns.

Watch whether OneOncology continues to support U.S. Healthcare Solutions operating margin going forward.

Monitor whether adjusted operating income and free cash flow stay on the guided track despite rising net interest expense.

Check how much GLP-1 mix pressure weighs on gross margin, and whether it is offset by growth in specialty pharmaceuticals and international logistics.